Our study showed that blockage of PD-1/PD-L1 could reactivate CD8+ T cells when co-cultured with STAT5 constitutively activated leukemic cells, which provided the basis for using immune checkpoint inhibitor in STAT5 high-expressed AML patients. Here, CD8A is linked to acute myeloid leukemia.